Bicycle Therapeutics (BCYC)
NASDAQ: BCYC
· Real-Time Price · USD
8.68
0.48 (5.85%)
At close: May 29, 2025, 3:59 PM
8.70
0.29%
After-hours: May 29, 2025, 04:04 PM EDT
5.85% (1D)
| Bid | 7.82 |
| Market Cap | 600.33M |
| Revenue (ttm) | 25.73M |
| Net Income (ttm) | -203.27M |
| EPS (ttm) | -3.16 |
| PE Ratio (ttm) | -2.75 |
| Forward PE | -1.82 |
| Analyst | Buy |
| Ask | 8.95 |
| Volume | 227,903 |
| Avg. Volume (20D) | 372,160 |
| Open | 8.31 |
| Previous Close | 8.20 |
| Day's Range | 8.25 - 8.73 |
| 52-Week Range | 6.10 - 28.67 |
| Beta | 1.60 |
About BCYC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCYC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCYC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+13.9%
Bicycle Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
8 months ago
-7.59%
Bicycle Therapeutics shares are trading lower. The company announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate zelenectide pevedotin in metastatic urothelial cancer; BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist BT7480 in advanced solid tumors.
